NCT00418262View on ClinicalTrials.gov

Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD

PHASE3CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

April 22, 2015

Study Completion Date

April 22, 2015

Conditions
Fetal Alcohol SyndromeAttention Deficit Hyperactivity Disorder (ADHD)
Interventions
DRUG

Atomoxetine

Titrating with oral administration of 0.25 mg/kg, 0.50 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with food.

Trial Locations (1)

73117

OU Child Study Center, Oklahoma City

All Listed Sponsors
collaborator

Mark L. Wolraich

UNKNOWN

lead

University of Oklahoma

OTHER

NCT00418262 - Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD | Biotech Hunter | Biotech Hunter